Welcome to AdisInsight

Please enter your official email address

Email Address
Please enter your official email address

Your email address will be used to create a unique number used exclusively to identify you on AdisInsight. Your email address will not be stored or maintained within AdisInsight. Your unique identifier number will be stored in your browser data on your device. This will allow us to know it’s you when you access AdisInsight from your computer, tablet, or phone. To do this you will need to enter your email address the first time to visit AdisInsight from a new device. After that we will recognize you and you will not have to enter your email again unless you have deleted your browser data. We will use your unique identifier number to provide anonymous information to your subscribing organization to allow them to accurately assess the value AdisInsight delivers. For additional information on how we protect your personal information, please refer to our
privacy policy
.

At a glance

Most Recent Events

05 Jun 2018
Results assessing ability of HER2-E/ERBB2H biomarker to predict clinical outcomes presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

14 Aug 2013
The European Commission granted an additional indication for lapatinib to be used in combination with trastuzumab based on overall survival results in the HER2+, HR- metastatic breast cancer population within this trial, according to GlaxoSmithKline.